Home › NDC Lookup › J-codes › J0223
J0223

J0223 – Injection, givosiran, 0.5 mg · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 1 NDC crosswalked per 0.5 MG $120.915/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J0223 summary

J0223 is a HCPCS Level II J-code used to bill givosiran, 0.5 mg, billed per 0.5 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J0223: Givlaari

Code J0223 Billing unit 0.5 MG Payment limit $120.915/unit NDC-Crosswalk 1 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ0223
DescriptorInjection, givosiran, 0.5 mg
Billing unit0.5 MG
Payment limit / unit$120.915
Est. ASP / unit$114.071 est.
Mapped NDCs1
Data periodQ3 2026
Last updated2026-08-20

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$120.915
Est. ASP / unit
$114.071 est.
Est. after 2% sequester
$118.497
HCPCS dosage
0.5 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, givosiran, 0.5 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2020-07-01
Date added2020-07-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J0223 = 0.5 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J0223 WITH EST. MEDICARE PAY

1 NDC map to J0223. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($120.915/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
71336-1001-01 GIVLAARI givosiran sodium 189 mg/mL INJECTION, SOLUTION Alnylam 1 VIAL, SINGLE-USE in 1 CARTON (71336-1001... 189 mg/mL 378 $45,705.87 — ● Active CMS ASP
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period
Total Part B spend
$4.73M
Claims
105
Beneficiaries
38
Spend / beneficiary
$124,415.48
Spend / claim
$45,026.55
Trend by period
Where J0223 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #245 of 824
#240 EPIFIX 1 SQ CM** Q4186 $5.1M #241 PULMOZYME J7639 $5.07M #242 NUWIQ J7209 $5.04M #243 TIVDAK J9273 $4.8M #244 LUCENTIS J2778 $4.78M #245 GIVLAARI J0223 $4.73M #246 VONVENDI J7179 $4.7M #247 HYALGAN* J7321 $4.54M #248 INVEGA SUSTENNA J2426 $4.49M #249 CYCLOPHOSPHAMIDE(J90... J9072 $4.47M #250 TOFIDENCE Q5133 $4.45M
Total claims — #628 of 824
#623 COCOON MEMBRANE, PER... Q4264 109 #624 BYOOVIZ Q5124 109 #625 ACYCLOVIR SODIUM J0133 108 #626 ORBACTIV J2407 108 #627 EDETATE CALCIUM DISO... J0600 107 #628 GIVLAARI J0223 105 #629 DERMABIND FM, PER SQ... Q4313 102 #630 GAMASTAN J1460 100 #631 MEDROL* J7509 100 #632 PHENYLEPHRINE HCL-0.... J2371 99 #633 DILTIAZEM HCL-0.9% N... J1163 97

Full breakdown by period (2)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $4.73M 38 105 $124,415.48 $45,026.55
2025 (Q1-Q4) $21.82M 53 453 $411,719.32 $48,170.25
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$6.88M
Medicare paid
$5.31M
Submitted services
70,584
Denial rate
14.4%
Allowed / service
$113.81
Submitted charges
$16.89M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where J0223 is utilized

⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J0223 billing FAQ

What is HCPCS code J0223?
J0223 is a HCPCS Level II J-code used to bill Injection, givosiran, 0.5 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0223?
One unit of J0223 represents 0.5 MG. Report the number of units equal to the dose administered divided by 0.5 MG.
How many units of J0223 should I bill?
Divide the dose administered by the code's unit size (0.5 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0223?
The Medicare Part B payment limit is $120.915 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $118.497 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0223?
1 NDC currently map to J0223 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0223 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.